Bristol-myers Squibb Compnay

Innate Tumor Immunity, Inc.

Birstol-myers Squibb Company

Ashvinikumar V Gavai

Brian E Fink

Derek J Norris

Yufen Zhao

Wen-Ching Han

Daniel O'Malley

John S Tokarski

Patrice Gill

Harold A Mastalerz

Christine M Tarby

Claude A Quesnelle

Ping Chen

George V Delucca

Soong-Hoon Kim

Wayne D Vaccaro

Scott Hunter Watterson

Gregory D Vite

Liqi He

Hua Gong

Yong Zhang

Francis Lee

James Aaron Balog

Steven P Seitz

Weifang Shan

Ashok Vinayak Purandare

Tram N Huynh

Libing Chen

Dharmpal S Dodd

Guifen Zhang

Andrew James Nation

Shomir Ghosh

Michael A Poss

William R Roush

David K Williams

Kurt Zimmermann

Christopher P Mussari

Jay A Markwalder

David R Tortolani

Amy C Hart

Xiaopeng Sang

Walter Lewis Johnson

Honghe Wan

Jennifer Inghrim

Litai H Zhang

John F Kadow

Edward H Ruediger

Dolatrai M Vyas

Philip Michael Sher

Mark George Saulnier

William N Washburn

Gregory S Bisacchi

John E Starrett, Jr

Prasanna Sivaprakasam

Lalgudi S Harikrishnan

Andrew P Degnan

Muthoni G Kamau

Kathleen M Poss

William D Schmitz

Matthias Broekema

Sanjeev Gangwar

James R Corte

Qian Zhang

Wu Yang

Raj N Misra

Hai-Yun Xiao

Mark E Salvati

Denis E Ryono

Yufeng Wang

Jacques Y Roberge

Yam B Poudel

Mikkel V Debenedetto

George L Trainor

Timur Gungor

Peter T Cheng

John Kenneth Dickson, Jr

Haiquan Fang

Qiang Cong

Bin Zheng

Vijay T Ahuja

Chong-qing Sun

Matthew D Hill

Pierre Dextraze

David P Rotella

Jean-Paul Daris

Amarendra B Mikkilineni

Shankar Swaminathan

Andrew Forrest Donnell

Roy J Vaz

Junying Fan

Sunil Kumar Mandal

Bin Chen

Arvind Mathur

Joel Francis Austin

Jeffrey A Deskus

Hong Huang

Mikkel V DeBenedetto

Victor R Guarino

Philippe Lapointe

Michael Wichroski

Bharat P Patel

The present invention provides compounds of Formula (I), wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

NLRP3 modulators

Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

1-pyrazolo[4,3-]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists

The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

The present invention provides compounds of Formula (I), (II) or (III): (I), (II), (III), wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

The present invention provides compounds of Formula (I): Formula (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

The invention relates generally to compounds that are Mer-Ax1 inhibitors, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

Uracil derivatives as Mer-AXL inhibitors

The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human). 

The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Carbazole compounds useful as bromodomain inhibitors

The present invention is directed to tricyclic compounds of formula (I), pharmaceutically acceptable compositions comprising compounds of the invention and said compositions for use in methods for the treatment of various disorders in particular cancer. 

5H-pyrido[3,2-B]indole compounds as anticancer agents

The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Tricyclic compounds as anticancer agents

Growing community of inventors

Princeton Junction, NJ, United States of America

Ashvinikumar V Gavai